Home › Research › Laboratory science
The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial
Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, Gao J, Budda B, Park LQ, Gupta R, Li C, Shi L, et al.. Nature Medicine, 2026-03-05
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Triggering receptor expressed on myeloid cells 2 (TREM2) regulates microglial function and is implicated in Alzheimer's disease (AD) pathogenesis. Here we conducted a phase 2, randomized, double-blind, placebo-controlled trial of a humanized TREM2 agonistic monoclonal antibody in 381 participants with early AD. Participants were randomized (1:1:1:1) to receive AL002 (15 mg kg -1 , 40 mg kg -1 or 60 mg kg -1 ) or placebo intravenously every 4 weeks for 48-96 weeks. AL002 demonstrated sustained target engagement and pharmacodynamic responses in the central nervous system, as demonstrated by reductions in soluble TREM2 and increases in osteopontin in cerebrospinal fluid, respectively. The study did not meet the primary endpoint of change from baseline in the Clinical Dementia Rating-Sum of Boxes score (versus placebo) (least squares mean difference versus placebo (95% confidence interval) at week 96: 15 mg kg -1 -0.31 (-1.61 to 0.98), 40 mg kg -1 0.13 (-1.18 to 1.43) and 60 mg kg -1 -0.17 (-1.49 to 1.15); P > 0.05 from mixed-effects model for repeated measures). The most frequent treatment-emergent adverse events were magnetic resonance imaging changes resembling amyloid-related imaging abnormalities (ARIA). This first trial of a TREM2 agonistic antibody in early AD was negative but provides findings relevant to the study of TREM2 therapeutics and ARIA. ClinicalTrials.gov: NCT04592874 .
What this study adds
Evidence grade: Null result
The record lists 381 participants. The most frequent treatment-emergent adverse events were MRI changes resembling amyloid-related imaging abnormalities, so this treatment was negative for clinical benefit in this trial.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Mummery, C. J., Mayorga, A. J., Simmons, A., Chow, T. W., Burgess, B., Nguyen, T., et al. (2026). The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature Medicine. https://doi.org/10.1038/s41591-026-04273-1
Vancouver
Mummery CJ, Mayorga AJ, Simmons A, Chow TW, Burgess B, Nguyen T, et al. The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial. Nature Medicine. 2026. doi:10.1038/s41591-026-04273-1. PMID: 41787076.
BibTeX
@article{mummery2026-41787076,
author = {Mummery, C. J. and Mayorga, A. J. and Simmons, A. and Chow, T. W. and Burgess, B. and Nguyen, T. and Gao, J. and Budda, B. and Park, L. Q. and Gupta, R. and Li, C. and Shi, L. and others},
title = {{The TREM2 agonistic antibody AL002 in early Alzheimer's disease: a phase 2 randomized trial}},
journal = {Nature Medicine},
year = {2026},
doi = {10.1038/s41591-026-04273-1},
pmid = {41787076},
url = {https://doi.org/10.1038/s41591-026-04273-1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- AL002 demonstrated sustained target engagement and pharmacodynamic responses in the central nervous system, as demonstrated by reductions in soluble TREM2 and increases in osteopontin in cerebrospinal fluid, respectively.
- The study did not meet the primary endpoint of change from baseline in the Clinical Dementia Rating-Sum of Boxes score (versus placebo) (least squares mean difference versus placebo (95% confidence interval) at week 96: 15 mg kg -1 -0.31 (-1.61 to 0.98), 40 mg kg -1 0.13 (-1.18 to 1.43) and 60 mg kg -1 -0.17 (-1.49 to 1.15); P > 0.05 from mixed-effects model for repeated measures).
Why it matters
In this phase 2 trial of 381 participants with early Alzheimer's disease, the TREM2 agonistic antibody AL002 did not meet the primary endpoint of change in the Clinical Dementia Rating-Sum of Boxes score versus placebo, although it showed target engagement in the central nervous system. The most frequent treatment-emergent adverse events were MRI changes resembling amyloid-related imaging abnormalities, so this treatment was negative for clinical benefit in this trial.
Study details
- Study designphase-2-trial
- Participants381
- Effect sizeCDR-SB difference vs placebo at week 96: -0.31 (95% CI -1.61 to 0.98), 0.13 (-1.18 to 1.43), -0.17 (-1.49 to 1.15) for 15, 40, 60 mg/kg
- Evidence strengthNull-result
How this study scored 73/100
Published in a top-tier journal, and it is a mid-stage phase 2 trial. We have no data on free to read, so that was left out: it earned 72 of the 98 points we could judge it on, which is 73 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (Nature Medicine) |
| Journal's citation record | 4 / 4 | Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29) |
| Study design | 8 / 12 | A mid-stage phase 2 trial |
| Strength of evidence | 3 / 5 | Rated “null-result” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 2 / 4 | 381 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 31 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 15.5 citations a year over 2 year(s) since 2026 |
| Impact for its field and year | 6 / 6 | Cited 128.3× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 2 / 4 | Cited 31 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Giacomo Salvadore: h-index 29 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University College London: institution h-index 2,029 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 6 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 41787076) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 72 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 72 of the 98 points we could judge it on is 73 out of 100. |
| Total | 73 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Laboratory science from nearby years
Also tagged “r47h”
363 studies in the library carry the topic tag “r47h”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 363 tagged studies.